outcome | cpnp.org

Home
About CPNP
- Why Join CPNP
- Board of Directors
- Past Presidents
- Committees & Task Forces
- Awards
- CPNP Foundation
- Corporate Sponsorships
  - Sponsor Program
  - Sponsors
- Information for Patients
- Contact CPNP
Education
- April 2013 Annual Meeting in Colorado Springs, CO
- April 2014 Annual Meeting in Phoenix, AZ
- CPNP University Online Courses
- Drug-Induced Movement Disorders Training DVD
- Psychiatric Pharmacotherapy for Nurses
- Other Meetings
- Find More Resources in My CPNP
  - My CPNP Presentations & Exams
  - My CPNP ACPE Transcript Center
BCPP
- BCPP Exam Preparation
  - BCPP Exam Preparation
  - Certification FAQ
- BCPP Recertification
Careers/Residencies
Member Center
- Member Toolkit
- Email List
- Member Directory
- CPNP Documents and Reports
- Member Hubs
  - Pharmacy Student Hub
  - New Practitioner Hub
Resources
Gov't and Prof Affairs
- Comprehensive Medication Management
- Government Affairs
  - Contacting Legislators and Policy Makers
  - Medicare Coverage Initiative with ACCP
- Position/White Papers
  - Psychiatric Pharmacy Manifesto
  - Psychiatric Pharmacist Integration into the Medical Home Model
My CPNP
- Edit My Profile
- My Disclosures of Interest
- My Workspaces
- My Presentations & Exams
- My Volunteer Profile
- My CPNP Transcript Center
- My Opportunities

outcome

Failure of natalizumab to prevent relapses in neuromyelitis optica.

Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69(2):239-45. doi:10.1001/archneurol.2011.216.

Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort.

Moghekar A, Goh J, Li M, Albert M, O'Brien RJ. Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort. Arch Neurol. 2012;69(2):246-50. doi:10.1001/archneurol.2011.732.

Mediterranean diet and white matter hyperintensity volume in the Northern Manhattan Study.

Gardener H, Scarmeas N, Gu Y, et al. Mediterranean diet and white matter hyperintensity volume in the Northern Manhattan Study. Arch Neurol. 2012;69(2):251-6. doi:10.1001/archneurol.2011.548.

Identifying subtle cortical gyral abnormalities as a predictor of focal cortical dysplasia and a cure for epilepsy.

Oster JM, Igbokwe E, Cosgrove RG, Cole AJ. Identifying subtle cortical gyral abnormalities as a predictor of focal cortical dysplasia and a cure for epilepsy. Arch Neurol. 2012;69(2):257-61. doi:10.1001/archneurol.2011.1002.

Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.

Havla JB, Pellkofer HL, Meinl I, et al. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol. 2012;69(2):262-4. doi:10.1001/archneurol.2011.1057.

Peripheral nerve toxic effects of nitrofurantoin.

Tan IL, Polydefkis MJ, Ebenezer GJ, Hauer P, McArthur JC. Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol. 2012;69(2):265-8. doi:10.1001/archneurol.2011.1120.

Pattern classification of volitional functional magnetic resonance imaging responses in patients with severe brain injury.

Bardin JC, Schiff ND, Voss HU. Pattern classification of volitional functional magnetic resonance imaging responses in patients with severe brain injury. Arch Neurol. 2012;69(2):176-81. doi:10.1001/archneurol.2011.892.

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurol

Kinkel PR, Dontchev M, Kollman C, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurol. Arch Neurol. 2012;69(2):183-90. doi:10.1001/archneurol.2011.1426.

Immunological markers of optimal response to natalizumab in multiple sclerosis.

Villar LM, García-Sánchez MI, Costa-Frossard L, et al. Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol. 2012;69(2):191-7. doi:10.1001/archneurol.2011.971.

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198-207. doi:10.1001/archneurol.2011.1538.